

PRODUCT MONOGRAPH

PrAA-AMILZIDE

Amiloride Hydrochloride and Hydrochlorothiazide Tablets

USP

5 mg / 50 mg

Diuretic-Antihypertensive

AA PHARMA INC.
1165 CREDITSTONE ROAD UNIT #1
Vaughan Ontario
L4K 4N7

Date of Revision:
June 06, 2019

Control Number: 224577

NAME OF DRUG

AA-AMILZIDE

Amiloride Hydrochloride and Hydrochlorothiazide Tablets
Each tablet contains 5 mg of amiloride hydrochloride and 50 mg of hydrochlorothiazide.

THERAPEUTIC CLASSIFICATION

Diuretic-Antihypertensive

ACTIONS

AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) is a diuretic/antihypertensive combining the potent natriuretic action of hydrochlorothiazide with the potassium-conserving property of amiloride hydrochloride. The mild diuretic and antihypertensive actions of amiloride hydrochloride are additive to the natriuretic, diuretic and antihypertensive activity of the thiazide while minimizing the loss of potassium and lessening the likelihood of acid-base imbalance. The onset of the diuretic action of AA-AMILZIDE is within 1 to 2 hours and this action appears to be sustained for approximately 24 hours.

Hydrochlorothiazide

Hydrochlorothiazide is a diuretic and antihypertensive agent. It affects the renal tubular mechanism of electrolyte reabsorption. Hydrochlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts and may cause a simultaneous, usually minimal, loss of bicarbonate. Natriuresis is usually accompanied by some loss of potassium.

The mechanism of the antihypertensive effect of thiazides may be related to the excretion and redistribution of body sodium. Hydrochlorothiazide usually does not decrease normal blood pressure.

The onset of the diuretic action of hydrochlorothiazide occurs in 2 hours and the peak action in about 4 hours. Diuretic activity lasts about 6 to 12 hours. Hydrochlorothiazide is eliminated rapidly by the kidney.

Amiloride Hydrochloride

Amiloride hydrochloride is an antikaliuretic drug with mild natriuretic diuretic and antihypertensive activity. These activities may be additive to the effects of thiazides or other saluretic-diuretic agents. The principal use of amiloride hydrochloride is to conserve potassium in selected patients receiving kaliuretic-diuretic agents. The action is not related to the level of aldosterone excretion. Amiloride hydrochloride is not an aldosterone antagonist. The drug acts directly on the distal portion of the nephron. Amiloride hydrochloride causes an increase in sodium excretion and a decrease in potassium and hydrogen ion excretion. Chloride excretion may remain unchanged or increase slowly with continued therapy. Approximately 50% of an oral dose is absorbed. Amiloride hydrochloride usually begins to act within 2 hours after an oral dose. Its effect on electrolyte excretion reaches a peak between 6 and 10 hours and lasts about 24 hours. Peak plasma levels are obtained in 3 to 4 hours and plasma half-life varies from 6 to 9 hours.

Amiloride hydrochloride is not metabolized by the liver. About 50% of a 20 mg dose of amiloride hydrochloride is excreted unchanged in the urine and 40% is excreted in the stool within 72 hours. In clinical studies amiloride hydrochloride was found to have little effect on glomerular filtration rate or renal blood flow.

Bioavailability studies were performed using normal human volunteers. The rate and extent of absorption after a single oral dose of 5 mg amiloride and 50 mg hydrochlorothiazide in the form of AA-AMILZIDE 5-50 mg and MODURET 5-50 mg was measured and compared. The results can be summarized as follows:

| <u>Amiloride HCl</u> | <u>MODURET (SD*)</u> | <u>AA-AMILZIDE (SD)</u> |
|----------------------|----------------------|-------------------------|
| AUC 0-24 (ng-hr/mL) | 62.5 (21.0) | 66.8 (18.4) |
| Cmax (ng/mL) | 6.0 (2.2) | 6.7 (2.4) |
| Tmax (hrs) | 3.8 (0.6) | 3.3 (0.8) |
| t 1/2 (hrs) | 8.2 (2.5) | 9.6 (3.8) |

Hydrochlorothiazide

| | | |
|---------------------|------------|------------|
| AUC 0-24 (ng-hr/mL) | 1603 (414) | 1654 (426) |
| Cmax (ng/mL) | 235 (73) | 242 (60) |
| Tmax (hrs) | 2.3 (1.0) | 2.4 (0.8) |
| t 1/2 (hrs) | 9.1 (3.3) | 10.0 (5.6) |

*SD = Standard Deviation

INDICATIONS AND CLINICAL USES

Fixed-dose combination drugs are not indicated for initial therapy. Patients should be titrated on the individual drugs. If the fixed combination represents the dosage so determined, its use may be more convenient in patient management. If during maintenance therapy dosage adjustment is necessary, it is advisable to use the individual drugs.

AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) is indicated in the maintenance therapy of:

- patients with hepatic cirrhosis with ascites and edema.
- patients with edema of cardiac origin or with arterial hypertension who are hypokalemic or in whom maintenance of normal potassium levels is considered to be clinically important i.e., digitalized patients, patients in whom adequate dietary intake of potassium is not feasible or patients with cardiac arrhythmias.

Use in Hepatic Cirrhosis with Ascites and Edema

Amiloride hydrochloride used alone may provide satisfactory diuresis with diminished potassium loss and with a reduced risk of metabolic alkalosis. In resistant cases amiloride hydrochloride may be used with kaliuretic-diuretic agents to help produce satisfactory diuresis, while maintaining a more balanced serum electrolyte pattern. As with all therapy for the ascites of hepatic cirrhosis, gradual weight loss and avoidance of electrolyte imbalance are the chief objectives (See PRECAUTIONS).

CONTRAINDICATIONS

Hyperkalemia

AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) should not be used in the presence of elevated serum potassium levels (See WARNINGS).

Antikaliuretic Therapy or Potassium Salts

Other antikaliuretic agents and potassium supplements are contraindicated in patients receiving AA-AMILZIDE (such combination therapy is commonly associated with rapid increases in plasma potassium levels).

Impaired Renal Function

Anuria, acute renal failure, severe or progressive renal disease and diabetic nephropathy are contraindications to the use of AA-AMILZIDE (See WARNINGS).

Hypersensitivity

AA-AMILZIDE is contraindicated in patients who are hypersensitive to either component, or to other sulfonamide-derived drugs.

WARNINGS

Hyperkalemia

Hyperkalemia, i.e. serum potassium levels over 5.5 mEq per litre, has been observed in some patients who received amiloride hydrochloride either alone or with diuretics. This has been noted particularly in elderly patients, in diabetic patients, and in hospitalized patients with hepatic cirrhosis or cardiac edema who had known renal impairment, were seriously ill, or were receiving vigorous diuretic therapy. Since fatalities have occurred in such patients, they should be monitored carefully for clinical, laboratory and electrocardiographic (ECG) evidence of hyperkalemia and for acidoses. Monitoring of the serum potassium level is important because hyperkalemia is not always associated with an abnormal ECG.

Warning signs or symptoms of hyperkalemia include paresthesias, muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and ECG abnormalities.

When abnormal, the ECG in hyperkalemia is characterized primarily by tall, peaked T waves or elevations from previous tracings. There may also be lowering of the R wave and increased depth of the S wave, widening and even disappearance of the P wave, progressive widening of the QRS complex, prolongation of the PR interval, and ST depression.

If hyperkalemia occurs in patients taking AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) the drug should be discontinued immediately. If the serum potassium level exceeds 6.5 mEq per liter, active measures should be taken to reduce it. Such measures include the intravenous administration of sodium bicarbonate solution or oral or parenteral glucose with a rapid-acting insulin preparation. If needed, a cation exchange resin such as sodium polystyrene sulfonate may be given orally or by enema. Patients with persistent hyperkalemia may require dialysis.

Diabetes Mellitus

In diabetic patients, hyperkalemia has been commonly reported with the use of amiloride hydrochloride, particularly if they have chronic renal disease or pre-renal azotemia. Some deaths occurred in this last group of patients. Therefore, if therapy with amiloride hydrochloride is considered essential, the drug should be used with caution in diabetic or suspected diabetic patients and only after first determining the status of renal function.

Careful monitoring of serum potassium levels is required throughout the therapy.

One patient with poorly controlled diabetes mellitus who became severely hyperkalemic while on amiloride hydrochloride died following two repeated intravenous glucose tolerance tests. Therefore, amiloride hydrochloride should be discontinued at least 3 days before glucose tolerance testing.

In diabetic patients, insulin requirements may be increased, decreased or unchanged due to the hydrochlorothiazide component. Diabetes mellitus which has been latent may become manifest during administration of thiazide diuretics.

Metabolic or Respiratory Acidosis

Antikaliuretic therapy should be instituted only with caution in patients in whom respiratory or metabolic acidosis may occur, such as patients with cardiopulmonary disease or diabetes. If AA-AMILZIDE is given to these patients, frequent monitoring of acid-base balance is necessary. Shifts in acid-base balance alter the ratio of extracellular/intracellular potassium, and the development of acidosis may be associated with rapid increases in serum potassium levels.

Impaired Renal Function

Patients with impaired renal function other than those listed under CONTRAINDICATIONS and who have BUN levels over 30 mg per 100 ml, serum creatinine levels over 1.5 mg per 100 ml, or blood urea values over 60 mg per 100 ml should not receive the drug without careful, frequent monitoring of serum electrolytes, creatinine and BUN levels. Potassium retention associated with the use of AA-AMILZIDE is accentuated in the presence of renal impairment and may result in the rapid development of hyperkalemia.

Prolongation of amiloride hydrochloride excretion was observed in patients with renal impairment.

Ophthalmologic

Acute Myopia and Secondary Angle-Closure Glaucoma

Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss.

The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulphonamide or penicillin allergy.

Carcinogenesis and Mutagenesis

Non-melanoma skin cancer:

An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of the skin] after hydrochlorothiazide therapy was reported in some epidemiological studies. The risk may be higher with increasing cumulative use (see ADVERSE REACTIONS, Post Market Adverse Drug Reactions). The photosensitizing action of hydrochlorothiazide may be a possible mechanism for NMSC (see TOXICOLOGY, Carcinogenicity – Hydrochlorothiazide).

Patients taking hydrochlorothiazide should be informed of the potential risk of NMSC. They should be advised to regularly check their skin for new lesions as well as changes to existing ones, and to promptly report any suspicious skin lesions. Patients should also be advised to limit exposure to sunlight, to avoid the use of indoor tanning equipment, and to use adequate protection (e.g. a broad spectrum sunscreen with a SPF of 30 or higher, clothing, and a hat) when exposed to sunlight or UV light to minimize the risk of skin cancer.

Alternatives to hydrochlorothiazide may be considered for patients who are at a particularly high risk for NMSC (e.g., light coloured skin, known personal or family history of skin cancer, ongoing immunosuppressive therapy, etc.) (see ADVERSE REACTIONS, Post Market Adverse Drug Reactions).

Photosensitivity

Photosensitivity reactions have been reported with the use of thiazide diuretics.

If photosensitivity reactions occur during treatment with hydrochlorothiazide-containing drugs, treatment should be stopped.

PRECAUTIONS

Electrolyte Imbalance and BUN Increases

Hyponatremia and hypochloremia may occur during the use of AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride). Hypokalemia may also occur although the incidence is less than with thiazides alone. Any chloride deficit is usually mild and may be corrected by the use of ammonium chloride (except in patients with hepatic disease) and largely prevented by a near normal salt intake. Increases in BUN levels have been reported and have usually accompanied vigorous fluid elimination, especially when diuretic combinations were used in seriously ill patients, such as those who have hepatic cirrhosis with ascites and metabolic alkalosis, or those with resistant edema. Therefore, careful monitoring of serum electrolytes and BUN levels is important when using AA-AMILZIDE. In patients with impaired renal function azotemia may be precipitated or increased by hydrochlorothiazide. Careful monitoring of such patients is therefore necessary. If increasing azotemia and oliguria occur during treatment, AA-AMILZIDE should be discontinued.

Effects Related to Diuresis in Cirrhotic Patients

Patients with hepatic cirrhosis and ascites are intolerant of acute shifts in electrolyte balance and often have pre-existing hypokalemia as a result of associated secondary hyperaldosteronism. When oral diuretic therapy is used, these patients should be carefully monitored and diuresis should be gradual.

Hepatic encephalopathy, manifested by tremors, confusion, and coma, has been reported in association with amiloride hydrochloride therapy.

In cirrhotic patients receiving amiloride hydrochloride alone, jaundice associated with the underlying disease process has deepened in a few instances, but the relationship to the drug is uncertain.

Other Precautions

Thiazides may decrease serum PBI levels without signs of thyroid disturbance.

Calcium excretion is decreased by hydrochlorothiazide and magnesium excretion is increased.

Pathological changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed in a few patients on prolonged thiazide therapy. The common complications of hyperparathyroidism such as renal lithiasis, bone resorption and peptic ulceration have not been seen. Thiazides should be discontinued before carrying out tests for parathyroid function.

Hyperuricemia may occur or gout may be precipitated.

Patients should be observed regularly for the possible occurrence of liver dysfunction, idiosyncratic reactions, or blood dyscrasias.

Sensitivity reactions to thiazides may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported with the thiazides.

Pregnancy

Because clinical experience is limited, AA-AMILZIDE is not recommended for use during pregnancy.

Teratologic studies with amiloride hydrochloride in rabbits and mice revealed no evidence of harm to the fetus. Reproduction studies in rats showed no evidence of impaired fertility. At approximately 5 or more times the expected maximum daily dose for humans, some toxicity was seen in adult rats and rabbits and a decrease in rat pup growth and survival occurred.

In rats, a trace of drug crossed the placental barrier.

Thiazides cross the placental barrier and appear in the cord blood. Therefore, the use of AA-AMILZIDE when pregnancy is present or suspected requires that the benefits of the drug be weighed against possible hazards to the fetus. These hazards include fetal or neonatal jaundice, thrombocytopenia and possibly other side effects that have occurred in the adult.

Nursing Mothers

It is not known whether amiloride hydrochloride is excreted in human milk. In rats, secretion of amiloride hydrochloride in milk has been demonstrated. Thiazides appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, if the use of AA-AMILZIDE is deemed essential, the patient should stop nursing.

Pediatric Use

The safety for use of amiloride hydrochloride in children has not been established: therefore, AA-AMILZIDE is not recommended in the pediatric age group.

Drug Interactions

The antihypertensive effect of the drug may be enhanced in the post-sympathectomy patient.

DRUG INTERACTIONS

Drug-Drug Interactions:

| Proper Name | Ref. | Effect | Clinical comment |
|---|-------------|---|---|
| Alcohol, barbiturates, or narcotics | C | Potential of orthostatic hypotension may occur. | Avoid alcohol, barbiturates or narcotics, especially with initiation of therapy. |
| Amphotericin B | T | Amphotericin B increases the risk of hypokalemia induced by thiazide diuretics. | Monitor serum potassium level. |
| Antidiabetic agents (e.g. insulin and oral hypoglycemic agents) | CT | Thiazide-induced hyperglycemia may compromise blood sugar control. Depletion of serum potassium augments glucose intolerance. | Monitor glycemic control, supplement potassium if necessary, to maintain appropriate serum potassium levels, and adjust diabetes medications as required. |
| Antihypertensive drugs | CT | Hydrochlorothiazide may potentiate the action of other antihypertensive drugs (e.g. guanethidine, methyl dopa, beta-blockers, vasodilators, calcium channel blockers, ACEI, ARB, and direct renin inhibitors). | |
| Antineoplastic drugs, including cyclophosphamide and methotrexate | C | Concomitant use of thiazide diuretics may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects. | Hematological status should be closely monitored in patients receiving this combination. Dose adjustment of cytotoxic agents may be required. |
| Bile acid sequestrants, e.g. cholestyramine | CT | Bile acid sequestrants bind thiazide diuretics in the gut and impair gastrointestinal absorption by 43-85%. Administration of thiazide 4 hours after a bile acid sequestrant reduced absorption of hydrochlorothiazide by 30-35%. | Give thiazide 2-4 hours before or 6 hours after the bile acid sequestrant. Maintain a consistent sequence of administration. Monitor blood pressure, and increase dose of thiazide, if necessary. |
| Calcium and vitamin D supplements | C | Thiazides decrease renal excretion of calcium and increase calcium release from bone. | Monitor serum calcium, especially with concomitant use of high doses of calcium supplements. Dose reduction or withdrawal of calcium and/or vitamin D supplements |

| Proper Name | Ref. | Effect | Clinical comment |
|---|-------|---|--|
| | | | may be necessary. |
| Carbamazepine | C | Carbamazepine may cause clinically significant hyponatremia. Concomitant use with thiazide diuretics may potentiate hyponatremia. | Monitor serum sodium levels. Use with caution. |
| Corticosteroids, and adrenocorticotrophic hormone (ACTH) | T | Intensified electrolyte depletion, particularly hypokalemia, may occur. | Monitor serum potassium, and adjust medications, as required. |
| Digoxin | CT | Thiazide-induced electrolyte disturbances, i.e. hypokalemia, hypomagnesemia, increase the risk of digoxin toxicity, which may lead to fatal arrhythmic events. | Concomitant administration of hydrochlorothiazide and digoxin requires caution. Monitor electrolytes and digoxin levels closely. Supplement potassium or adjust doses of digoxin or thiazide, as required. |
| Drugs that alter GI motility, i.e., anticholinergic agents, such as atropine and prokinetic agents, such as metoclopramide, domperidone | CT, T | Bioavailability of thiazide diuretics may be increased by anticholinergic agents due to a decrease in gastrointestinal motility and gastric emptying. Conversely, prokinetic drugs may decrease the bioavailability of thiazide diuretics. | Dose adjustment of thiazide may be required. |
| Gout medications (allopurinol, uricosurics, xanthine oxidase inhibitors) | T, RC | Thiazide-induced hyperuricemia may compromise control of gout by allopurinol and probenecid. The co-administration of hydrochlorothiazide and allopurinol may increase the incidence of hypersensitivity reactions to allopurinol. | Dosage adjustment of gout medications may be required. |
| Lithium | CT | Thiazide diuretics reduce the renal clearance of lithium and add a high risk of lithium toxicity. | Concomitant use of thiazide diuretics with lithium is generally not recommended. If such use is deemed necessary, reduce lithium dose by 50% and monitor lithium levels closely. |
| Nonsteroidal anti-inflammatory drugs (NSAID) | CT | NSAID-related retention of sodium and water antagonises the diuretic and antihypertensive effects of thiazides. NSAID-induced inhibition of renal prostaglandins leading to decreases of renal blood flow, along with thiazide-induced decreases in GFR may lead to | If combination use is necessary, monitor renal function, serum potassium, and blood pressure closely. Dose adjustments may be required. |

| Proper Name | Ref. | Effect | Clinical comment |
|--|------|---|---|
| | | acute renal failure. Patients with heart failure may be at particular risk. | |
| Selective serotonin reuptake inhibitors (SSRIs, e.g. citalopram, escitalopram, sertraline) | T, C | Concomitant use with thiazide diuretics may potentiate hyponatremia. | Monitor serum sodium levels. Use with caution. |
| Skeletal muscle relaxants of the curare family, e.g., tubocurare | C | Thiazide drugs may increase the responsiveness of some skeletal muscle relaxants, such as curare derivatives. | |
| Topiramate | CT | Additive hypokalemia. Possible thiazide-induced increase in topiramate serum concentrations. | Monitor serum potassium and topiramate levels. Use potassium supplements, or adjust topiramate dose as necessary. |

Legend: C = Case Study; RCS = Retrospective Cohort Study; CT = Clinical Trial; T = Theoretical

ADVERSE REACTIONS

While rare, the most serious adverse effect of AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) is symptomatic hyperkalemia. Other metabolic changes that occur are asymptomatic hyperkalemia, hypokalemia and hypochloremia.

The following incidence of other adverse reactions was reported in patients treated with a combination of hydrochlorothiazide and amiloride hydrochloride.

| | <u>Incidence ≥3%</u> | <u>Incidence >1%- <3%</u> | <u>Incidence ≤1%</u> |
|--|--|---|---|
| <u>Gastro- Intestinal</u> (In 7.1% of patients) | Nausea/anorexia (3.7%) | Diarrhea Gastrointestinal pain. Abdominal pain. | Constipation GI bleeding GI disturbance Appetite changes Abdominal fullness Hiccups Thirst Vomiting Anorexia Flatulence Bad taste |
| <u>Central Nervous System</u> (In 13.9% of patients) | Headache (7.8%) Dizziness (6.1%) Weakness (4.0%) | | Paresthesia/ numbness Stupor Vertigo Insomnia Nervousness Depression Sleepiness Mental confusion Visual disturbance |
| <u>Dermatologic</u> (In 5.2% of patients) | Rash (3.4%) | Pruritus | Flushing |

| | <u>Incidence >3%</u> | <u>Incidence >1%- <3%</u> | <u>Incidence ≤1%</u> |
|--|-------------------------|---------------------------------|---|
| <u>Cardiovascular</u> (In 4.3% of patients) | | Arrhythmia | Tachycardia Digitalis Toxicity Orthostatic hypotension Angina pectoris |
| <u>Musculoskeletal</u> (In 3.7% of patients) | | Leg ache | Muscle cramps/ spasm Joint pain Chest pain Back pain |
| Respiratory (In 2.6% of patients) | | Dyspnea | Nasal congestion |
| <u>Urogenital</u> (In 1.7% of patients) | | | Impotence Nocturia Dysuria Incontinence |
| <u>Endocrine</u> (In 0.9% of patients) | | | Gout Dehydration |
| <u>Other</u> (In 2.6% of patients) | | Fatigue/tiredness | Malaise |

Other adverse reactions that have been reported with the individual components are listed below:

CARDIOVASCULAR

Necrotizing angiitis (vasculitis, cutaneous vasculitis)

GASTROINTESTINAL

Abnormal liver function
Jaundice (intrahepatic cholestatic jaundice)
Activation of pre-existing peptic ulcer
Cramping
Gastric irritation
Pancreatitis
Dry mouth
Sialadenitis

ENDOCRINE

Glycosuria
Hyperglycemia
Hyperuricemia

HYPERSENSITIVITY

Urticaria
Anaphylactic reactions

RESPIRATORY

Respiratory distress including pneumonitis

SPECIAL SENSES

Photosensitivity
Transient blurred vision

Xanthopsia

HEMATOLOGIC

Agranulocytosis
Aplastic anemia
Hemolytic anemia
Leukopenia
Purpura
Thrombocytopenia
Neutropenia

OTHERS

Restlessness
Fever

Post-Market Adverse Drug Reactions

Non-melanoma skin cancer

Some pharmacoepidemiological studies have suggested a higher risk of squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) of the skin with increasing use of hydrochlorothiazide. A systematic review and meta-analysis undertaken by Health Canada suggested that, with important uncertainty, the use of hydrochlorothiazide for several years (>3 years) could lead to:

- 122 additional cases (95% CI, from 112 to 133 additional cases) of SCC per 1000 treated patients compared with non-use of hydrochlorothiazide (meta-analysis of 3 observational studies);
- 31 additional cases (95% CI, from 24 to 37 additional cases) of BCC per 1000 treated patients compared with non-use of hydrochlorothiazide (meta-analysis of 2 observational studies).

SYMPTOMS AND TREATMENT OF OVERDOSAGE

No data are available in regard to overdosage in humans with AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) or with the amiloride hydrochloride component.

The most common signs and symptoms to be expected from overdosage with AA-AMILZIDE are dehydration and electrolyte imbalance. Serum electrolytes should be carefully monitored with special attention to potassium levels.

Cardiac arrhythmias may be caused by abnormal potassium levels. Digitalized patients are especially prone to arrhythmias.

No specific information is available on the treatment of AA-AMILZIDE overdosage and no specific antidote is available. Treatment is symptomatic and supportive. Therapy with AA-AMILZIDE should be discontinued and the patient observed closely. Suggested measures include induction of emesis and/or gastric lavage.

It is not known whether the drug is dialyzable.

| |
|--|
| For management of a suspected drug overdose, contact your regional Poison Control Centre |
|--|

DOSAGE AND ADMINISTRATION

Optimal dosage should be established by the individual titration of the components.

Maintenance doses may be lower than those required to initiate diuresis; therefore, reduction in the daily dosage should be attempted when the patient's weight is stabilized. In cirrhotic patients, gradual weight reduction is especially desirable to reduce the likelihood of untoward reactions associated with diuretic therapy.

Hepatic Cirrhosis with Ascites and Edema

The usual maintenance dose of AA-AMILZIDE (hydrochlorothiazide and amiloride hydrochloride) is 1 tablet given once a day. The dosage should not exceed 4 tablets a day in single or divided doses.

Edema of Cardiac Origin

The usual maintenance dose of AA-AMILZIDE is 1 or 2 tablets given once a day or in divided doses. The dosage should not exceed 4 tablets a day. Therapy may be on an intermittent basis.

Hypertension

The usual maintenance dosage is 1 or 2 tablets given once a day or in divided doses. The dosage should not exceed 4 tablets a day.

DOSAGE FORMS, COMPOSITION AND PACKAGING


AA-AMILZIDE Tablets, containing 5 mg amiloride hydrochloride and 50 mg hydrochlorothiazide, are peach coloured, diamond shaped tablets, scored and identified APO above the score, 5/50 below the score. Available in bottle of 1000.

In addition to the active ingredients, hydrochlorothiazide and amiloride, each tablet also contains the non-medicinal ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium bicarbonate and sunset yellow aluminium lake 40 %.

CHEMISTRY

Hydrochlorothiazide

Structural Formula:



Molecular Formula: C₇H₈ClN₃O₄S₂

Molecular -Weight: 297.72 g/mol

Chemical Name


6-Chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1, 1-dioxide.

Description:

Hydrochlorothiazide is a white or practically white compound with low solubility in water, but readily soluble in dilute aqueous sodium hydroxide.

Amiloride hydrochloride

Structural Formula:



Molecular Formula: C₆H₈ClN₇O.HCl.

Molecular Weight: 266.1 g/mol

Chemical Name:

3,5-Diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide hydrochloride.

Description

Amiloride hydrochloride is a yellow to greenish yellow, odourless or practically odourless, crystalline compound, soluble in water.

PHARMACOLOGY

Hydrochlorothiazide

Hydrochlorothiazide has diuretic and antihypertensive activities. This compound increases the excretion of sodium and chloride in approximately equivalent amounts and causes a simultaneous, usually minimal loss of bicarbonate. The excretion of ammonia is reduced slightly by hydrochlorothiazide and the blood ammonia concentration may be increased. The excretion of potassium is increased slightly. Calcium excretion is decreased by hydrochlorothiazide and magnesium excretion is increased.

Hydrochlorothiazide is eliminated rapidly by the kidney. Its rate of elimination is decreased somewhat by the co-administration of probenecid without, however, an accompanying reduction in diuresis.

Amiloride hydrochloride

Amiloride hydrochloride is chemically unrelated to other known antikaliuretic or diuretic agents. It is a salt of a moderately strong base (pKa 8.7).

In rats and dogs, amiloride hydrochloride in an oral dose of 0.1 mg/kg or less increases the excretion of sodium and to a lesser extent, of chloride but does not increase the excretion of potassium. A potassium-retaining effect is seen in experimental animals, especially under conditions of high potassium excretion, as upon loading with potassium chloride, after pre-treatment with acetazolamide or thiazides, or in deoxycorticosterone-treated adrenalectomized rats. The natriuresis is accompanied by an increase in urinary pH, reflecting a decrease in hydrogen ion excretion. Following oral administration to dogs, amiloride hydrochloride increases the rate of sodium excretion less than do the more potent agents, but the moderate effect on sodium excretion has an extended duration. Natriuresis increases only moderately as the oral dose is increased from 0.25 to 4.0 mg/kg; this activity persists beyond 6 hours.

An increase in sodium excretion is produced when amiloride hydrochloride is given together with chlorothiazide, hydrochlorothiazide, or acetazolamide to rats. Amiloride hydrochloride antagonizes the kaliuretic effect of the other diuretic. Oral doses of amiloride hydrochloride (0.1 to 0.5 mg/kg) increase the excretion of sodium and decrease that of potassium in dogs given ethacrynic acid (1.0 mg/kg) or hydrochlorothiazide (0.5 mg/kg) orally.

Amiloride hydrochloride increases the Na^+/K^+ excretion ratio in adrenalectomized rats. In adrenalectomized rats treated with aldosterone, deoxycorticosterone, or hydrocortisone, amiloride hydrochloride not only reverses the steroid-induced sodium retention, but increases the Na^+/K^+ excretion ratio substantially above that of untreated adrenalectomized rats.

Stop-flow studies in dogs indicate that amiloride hydrochloride inhibits tubular secretion of potassium and reabsorption of sodium in the distal portion of the nephron. In renal clearance studies, 1.0 mg/kg intravenously did not affect glomerular filtration rate, effective renal plasma flow, or glucose reabsorption. An enzymatic basis for the renal action of amiloride hydrochloride has not been elucidated. It is not an inhibitor of carbonic anhydrase.

Amiloride hydrochloride given parenterally (2.5 to 5.0 mg/kg) to anesthetized dogs produces profound reduction of blood pressure and produces changes in the electrocardiogram. The effects which are coincident with the release of histamine into plasma, are not seen if the compound is injected slowly or if lower doses are given. A slight increase in gastric secretion and intestinal motility occurred after oral administration to dogs of 0.5 to 2.0 mg/kg. Pre-treatment of several days with amiloride hydrochloride in a dose of 5 mg/kg/day by mouth does not alter the response of dogs to ouabain.

TOXICOLOGY

Acute Toxicity:

| SPECIES | AMILORIDE HYDROCHLORIDE | HYDROCHLOROTHIAZIDE | Oral LD ₅₀ (mg/kg) |
|---------|----------------------------|---------------------|---|
| | | | AMILORIDE HYDROCHLORIDE / HYDROCHLOROTHIAZIDE 5:50 |
| MICE | 56 | >10,000 | 189 |
| RATS | 36-85 | >10,000 | 422 (FEMALES) 377 (MALES) |

Acute oral studies of fixed combinations in the mouse and rat showed that the toxicity was based primarily on the amiloride content.

Subacute and Chronic Toxicity

Amiloride Hydrochloride/Hydrochlorothiazide

Twelve-week and 25-week oral studies of the combination in the rat indicated the toxicity expected from the individual ingredients (fluid loss at high doses and hyperplasia of the adrenal zona glomerulosa). No evidence of drug interaction was seen. The high dose in the 12-week study (10 mg/kg of amiloride hydrochloride with 500 mg/kg of hydrochlorothiazide) was not well tolerated; 11 of 30 animals died.

The toxicity was related to effects on serum electrolytes.

In the dog, effects observed included dry nose and gums, diuresis, natriuresis, chloruresis, antikaluresis and hyperplasia of the adrenal zona glomerulosa.

Electrocardiographic changes suggestive of potassium retention were seen at high dose levels. A dose of 5/50 mg/kg resulted in deaths from electrolyte imbalance. A dose of 2.5/25 mg/kg increased to 4.0/40 mg/kg/day was tolerated for six months.

Amiloride Hydrochloride

MODERATE TO MARKED HYPERKALEMIA DEVELOPED AT HIGHER DOSES IN ALL SPECIES. SERUM SODIUM AND CHLORIDE WERE DECREASED.

Rats were given amiloride at oral daily doses of 2.5, 5, 10-15 mg/kg/day for up to 18 months. Doses of 10-15 mg/kg/day caused a high incidence of deaths, probably due to severe electrolyte imbalance.

In a 6 week study, GI ulcerations were observed in 1 of 4 dogs at 2.5 mg/kg and 2 of 4 dogs at 10 mg/kg.

Rats received amiloride hydrochloride by oral route at doses of 0, 2.5, 5.0, and 10 to 15 mg/kg for up to 80 weeks. Inhibition of weight gain occurred in male rats. Drug induced changes included alterations in urinary and serum electrolytes (which resulted in severe symptoms in the high dose group), reversible hyperplasia of the zona glomerulosa at all doses and renal tubular dilation at 10 mg/kg/day.

Dogs treated with oral doses of 0, 2, 4 and 8 mg/kg/day (base) for one year showed changes in body weight, water intake and serum electrolytes. Positive fecal occult blood occurred at a slightly greater incidence in treated animals but no evidence of gastrointestinal ulceration was seen. Dose-dependent hyperplasia of the zona glomerulosa of the adrenal was observed in all treated dogs.

Monkeys were given amiloride at oral doses up to 12 mg/kg/day, 5 days/week, for 49 weeks. Excitability and irritability, electrolyte imbalance and increased adrenal weights occurred at 12 mg/kg/day. It was reported that urinary excretion of aldosterone was increased in high dose animals.

Special Studies Relative to Adrenal Zona

Glomerulosa, Hyperplasia and Diabetes

Amiloride hydrochloride produced a dose-dependent hyperplasia of the zona glomerulosa of the adrenal cortex in rats and dogs, however, no adrenal hyperplasia occurred in monkeys, although adrenal weights were increased. In rats, reversibility of the hyperplasia was demonstrated after the drug was given for 58 weeks and the animals were observed for an additional 22 weeks. Hyperplasia has been shown to disappear in 19 to 30 days after cessation of treatment and the adrenals were normal within 30 to 58 days. The hyperplasia can be reduced by substitution of physiologic saline for drinking water. Hyperplasia of the adrenal zona glomerulosa occurred in maternal mice but not in the offspring in a teratogenic study. The hyperplasia is considered to be induced by alteration of serum electrolytes and/or inhibition of aldosterone activity.

No effect on carbohydrate metabolism was observed when the toxicity of amiloride hydrochloride was studied in obese diabetic Zucker rats and normal-thin rats. Amiloride hydrochloride had no adverse effect on glucose tolerance in acute experiments in rats or in a chronic study in dogs.

Amiloride/Hydrochlorothiazide Combination

Rats were given 5/100, 10/500 mg/kg amiloride/hydrochlorothiazide 5 days/week for 25 weeks. Animals at the high dose experienced high mortality rates. Dogs were given 1/5, 4/40 mg/kg amiloride/hydrochlorothiazide 5 to 7 days/week for 25 weeks and 5/50 mg/kg 7 days/week for 13 weeks. At higher doses the toxic effects in rats and dogs were adrenal zona glomerulosa hyperplasia, electrolyte imbalance, elevated BUN, ECG disturbances, and focal tubular fatty changes of the kidney.

Tumorigenicity Studies

No tumorigenic effect was observed when amiloride hydrochloride was administered for 92 weeks to mice at doses of up to 10 mg/kg/day and for 104 weeks to rats at doses of up to 8 mg/kg/day.

Reproductive Studies

Amiloride hydrochloride/hydrochlorothiazide combinations were administered orally to pregnant mice at dosage levels of 1/5, 5/25 and 5/50 mg/kg/day (12.5 times the expected maximum daily dose for humans) and to pregnant rabbits at dosage levels of 1.0/2.5, 1/5 and 4/20 mg/kg/day (10/20 times the expected maximum daily dose for humans). In a second study in pregnant rabbits, amiloride hydrochloride/hydrochlorothiazide was administered at dosage levels of 0.5/5, 1/10 and 2/20 mg/kg/day (5 times the expected maximum daily dose for humans). No teratogenic embryotoxic, fetotoxic, or maternotoxic effects attributable to treatment were observed in either species.

No effect on reproductive performance or fertility in albino rats given 2, 4, or 8 mg/kg/day amiloride base orally was noted. Growth rate and food consumption were reduced at the highest dose. Doses of 4 and 8 mg/kg/day were administered without effect during late gestation and growth. The high dose adversely affected pup survival and growth.

Carcinogenicity

Hydrochlorothiazide

According to the experimental data available, hydrochlorothiazide revealed inconsistent evidence of carcinogenic activity in rats and mice, with conflicting evidence of hepatic adenoma in male mice at the highest dose and adrenal pheochromocytoma in one rat study but not in another. Current evidence is inadequate to draw a clear conclusion for a carcinogenic effect of hydrochlorothiazide in animals.

The mutagenic potential was assessed in a series of *in vitro* and *in vivo* test systems. While some positive results were obtained *in vitro*, all *in vivo* studies provided negative results. Hydrochlorothiazide enhanced the UVA-induced formation of pyrimidine dimers *in vitro* and in the skin of mice following oral treatment. It is therefore concluded that although there is no relevant mutagenic potential *in vivo*, hydrochlorothiazide could enhance the genotoxic effects of UVA light. This mechanism of photosensitization could be associated with a higher risk for non-melanoma skin cancer.

REFERENCES

1. Antcliffe AC, Beevers DG, Hamilton M, Harpur JE. The use of amiloride hydrochloride in the correction of hypokalemic alkalosis induced by diuretics. *Postgrad Med J* 1971; 47: 644-647.
2. Bergstrom J, Friden AM. The effect of hydrochlorothiazide and amiloride administered together on muscle electrolytes in normal subjects. *Acta Med Scand* 1975; 197: 415-419.
3. Bull MB, Laragh JH. Amiloride, a potassium-sparing natriuretic agent. *Circulation* 1968; 37: 45-53.
4. Castenfors H. Long term effect of timolol and hydrochlorothiazide, or hydrochlorothiazide and amiloride in essential hypertension. *Eur J Clin Pharmacol* 1977; 12: 97-103.
5. George CF. Amiloride handling in renal failure. *Br J Pharmacol* 1980; 9: 94-95.
6. Gombos EA, Freis ED, Moghadam A. Effects of MK-870 in normal subjects and hypertensive patients. *N Eng J Med* 1966; 275:1215-1220.
7. Kohvakka A, Eisalo A, Manninen V. Maintenance of potassium balance during diuretic therapy. *Acta Med Scand* 1979; 205: 319-324.
8. Larochelle P, Logan AG. Hydrochlorothiazide-amiloride versus hydrochlorothiazide alone for essential hypertension: effects on blood pressure and serum potassium level. *Canad Med Assoc J* 1985; 132: 801-805.
9. Leary WP, Reyes AJ, Van der Byl K. Effects of a combination of hydrochlorothiazide and amiloride on urinary magnesium excretion in healthy adults. *Curr Ther Res* 1984; 35: 293-300.
10. McMahon FG, Okun R, Vaicaitis JS. Multicenter study of amiloride/hydrochlorothiazide once-daily and triamterene/hydrochlorothiazide twice-daily: antihypertensive and potassium-sparing effects. *Curr Ther Res* 1983; 34: 357-364.
11. Moduret. Merck Sharp & Dohme Canada Ltd.; Product Monograph: Date of Revision June 11, 1982.
12. Multicenter Diuretic Cooperative Study Group. Multiclinic comparison of amiloride, hydrochlorothiazide plus amiloride in essential hypertension. *Arch Intern Med* 1981; 141:482-486.
13. Physicians Desk Reference 1988; 1370- 1372.
14. RuilopeL, Alcazar JM, Diaz VP, Jarillo MD, Millet VG, Rodicio JL. A fixed combination of essential hypertension. *Clin Ther* 180; 3: 15-20.
15. Senewiratne B, Sherlock S. Amiloride (MK 870)in patients with ascites due to cirrhosis of the liver. *Lancet* 1968; 1: 120-122.
16. Svendsen UG, Ibsen H, Rasmussen S, Leth A, Nielsen MD, Dige-Petersen H, Giese J. Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated.hypertensive patients. *Clin Pharmacol Ther* 1983; 34: 448-453.

17. U.S.F.D.A. Documents; SBOA NDA 18-200, 18-201; 1981. 1-84. Review and Evaluation of Pharmacology and Toxicology Data NDA 18-201; 10/24/79. 1-11. Pharmacologist's Summary NDA 11-835 03/22/67.1-2.
18. Van Soeren F. The antihypertensive and biochemical effects of hydrochlorothiazide/amiloride (Moduretic) versus chlorthalidone. *J Int Med Res* 1980; 8: 132-135.
19. Venkata C, Holland 08, Kaplan NM. Attenuation of diuretic-induced hypokalemia by amiloride, a potassium-sparing agent. *J Clin Pharmacol* 1981; 21: 484-487.
20. Whight C, Morgan T, Carney S, Wilson M. Diuretics, cardiac failure and potassium depletion: a rational approach. *Med J Aust* 1974; 2: 831-833.
21. Yamada S, Reynolds TB. Amiloride (MK-870), a new antikaluretic diuretic: comparison to other antikaluretic diuretics in patients with liver disease and ascites. *Gastroenterology* 1970; 59: 833-841.
22. Zsoter TT, Hart F, Radde IC: Mechanism of antihypertensive action of prolonged administration of hydrochlorothiazide in rabbit and dog. *Circ Res* 1970; 27: 717-725.

PART III: CONSUMER INFORMATION

Pr AA-AMILZIDE

**(Amiloride Hydrochloride and Hydrochlorothiazide Tablets USP)
5 mg / 50 mg**

Read this carefully before you start taking AA-AMILZIDE and each time you get a refill. This leaflet is a summary and will not tell you everything about AA-AMILZIDE. Talk to your doctor, nurse, or pharmacist about your medical condition and treatment and ask if there is any new information about AA-AMILZIDE.

ABOUT THIS MEDICATION

What the medication is used for:

AA-AMILZIDE is used in adults for:

- Swelling of the hands, ankles or feet in patients with hepatic cirrhosis (a liver disease).
- Patients with swelling of the hands, ankles or feet caused by heart problems or patients with high blood pressure (hypertension) who have low levels of potassium in their blood (hypokalemia) or who need to maintain normal levels of potassium.

What it does:

AA-AMILZIDE contains a combination of 2 drugs, amiloride hydrochloride and hydrochlorothiazide:

- amiloride hydrochloride helps the body lose excess salt but keep a normal amount of potassium (an electrolyte) in the blood.
- Hydrochlorothiazide is a diuretic or “water pill” that increases urination. This lowers blood pressure.

This medicine does not cure high blood pressure. It helps to control it. Therefore, it is important to continue taking AA-AMILZIDE regularly even if you feel fine.

When it should not be used:

Do not take AA-AMILZIDE if you:

- Are allergic to amiloride hydrochloride or hydrochlorothiazide, or to any non-medicinal ingredient in the formulation.
- Are allergic to any sulfonamide-derived drugs (sulfa drugs); most of them have a medicinal ingredient that ends in “-MIDE”.
- Have difficulty urinating or produce no urine.
- Have high potassium levels (hyperkalemia).
- Have kidney failure, severe or worsening kidney disease or problems with your kidneys because of diabetes (diabetic nephropathy).
- Are using any form of potassium supplementation.
- Are taking any other potassium-conserving medications or “water pills”.
- Are breastfeeding. AA-AMILZIDE passes into breast milk.
- Have one of the following rare hereditary diseases:
 - Galactose intolerance
 - Lapp lactase deficiency
 - Glucose-galactose malabsorption

Because lactose is a non-medicinal ingredient in AA-AMILZIDE.

What the medicinal ingredients are:

amiloride hydrochloride and hydrochlorothiazide.

What the non-medicinal ingredients are:

Colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium bicarbonate and sunset yellow aluminium lake 40 %

What dosage forms it comes in:

Tablet; amiloride hydrochloride 5 mg and hydrochlorothiazide 50 mg.

WARNINGS AND PRECAUTIONS

BEFORE you use AA-AMILZIDE talk to your doctor, nurse, or pharmacist if you:

- Are allergic to penicillin.
- Have diabetes, liver, heart or kidney disease.
- Have cardiopulmonary disease (disease involving both the lungs and heart).
- Had a sympathectomy (a surgery to remove part of a nerve from your spinal cord).
- Have lupus or gout.
- Have a stomach (peptic) ulcer.
- Are dehydrated or suffer from excessive vomiting, diarrhea, or sweating.
- Are pregnant or thinking of becoming pregnant.
- Are less than 18 or over 65 years of age.
- Have had skin cancer or have a family history of skin cancer.
- Have a greater chance of developing skin cancer because you have light-coloured skin, get sunburned easily, or are taking drugs to suppress your immune system.

Risk of skin cancer:

AA-AMILZIDE contains hydrochlorothiazide. Treatment with hydrochlorothiazide may increase the risk of developing non-melanoma skin cancer. The risk is higher if you have been taking AA-AMILZIDE for many years (more than 3) or at a high dose.

While taking AA-AMILZIDE:

- Make sure to regularly check your skin for any new lesions. Check areas that are most exposed to the sun, such as the face, ears, hands, shoulders, upper chest and back.
- Limit your exposure to the sun and to indoor tanning. Always use sunscreen (SPF-30 or higher) and wear protective clothing when going outside.
- Talk to your doctor immediately if you get more sensitive to the sun or UV light or if you develop an unexpected skin lesion (such as a lump, bump, sore, or patch) during the treatment.

Hydrochlorothiazide in AA-AMILZIDE can cause Sudden Eye Disorders:

- **Myopia:** sudden nearsightedness or blurred vision.
- **Glaucoma:** an increased pressure in your eyes, eye pain. Untreated, it may lead to permanent vision loss.

These eye disorders are related and can develop within hours to weeks of starting AA-AMILZIDE.

You may become sensitive to the sun while taking AA-AMILZIDE. Exposure to sunlight should be minimized until you know how you respond.

Driving and using machines: Before you perform tasks which may require special attention, wait until you know how you respond to AA-AMILZIDE. Dizziness, lightheadedness, or fainting can especially occur after the first dose and when the dose is increased.

INTERACTIONS WITH THIS MEDICATION

As with most medicines, interactions with other drugs are possible. Tell your doctor, nurse, or pharmacist about all the medicines you take, including drugs prescribed by other doctors, vitamins, minerals, natural supplements, or alternative medicines.

The following may interact with AA-AMILZIDE:

- Adrenocorticotrophic hormone (ACTH) used to treat West Syndrome.
- Alcohol, barbiturates (sleeping pills), or narcotics (strong pain medications). They may cause low blood pressure and dizziness when you go from lying or sitting to standing up.
- Amphotericin B, an antifungal drug.
- Anticancer drugs, including cyclophosphamide and methotrexate.
- Antidepressants, in particular selective serotonin reuptake inhibitors (SSRIs), including citalopram, escitalopram, and sertraline.
- Antidiabetic drugs, including insulin and oral medicines.
- Bile acid resins used to lower cholesterol.
- Calcium or vitamin D supplements.
- Corticosteroids used to treat joint pain and swelling.
- Digoxin, a heart medication.
- Drugs that slow down or speed up bowel function, including atropine, metoclopramide, and domperidone.
- Drugs used to treat epilepsy, including carbamazepine and topiramate.
- Gout medications, including allopurinol and probenecid.
- Lithium used to treat bipolar disease.
- Nonsteroidal anti-inflammatory drugs (NSAIDs), used to reduce pain and swelling. Examples include ibuprofen, naproxen, and celecoxib.
- Other blood pressure lowering drugs. When taken in combination with AA-AMILZIDE, they may cause excessively low blood pressure.
- Skeletal muscle relaxants used to relieve muscle spasms, including tubocurare.

PROPER USE OF THIS MEDICATION

Take AA-AMILZIDE exactly as prescribed. It is recommended to take your dose at about the same time every day.

AA-AMILZIDE can be taken with or without food. If AA-AMILZIDE causes upset stomach, take it with food or milk.

Usual Adult dose:

For Swelling of the hands, ankles or feet in Patients with Hepatic Cirrhosis: 1 tablet given once a day. The dosage should not exceed 4 tablets a day in single or divided doses.

For Swelling of the hands, ankles or feet caused by Heart Problems: 1 or 2 tablets given once a day or in divided doses. The dosage should not exceed 4 tablets a day.

For High Blood Pressure (Hypertension): 1 or 2 tablets given once a day or in divided doses. The dosage should not exceed 4 tablets a day.

Overdose:

If you think you have taken too much AA-AMILZIDE contact your doctor, nurse, pharmacist, hospital emergency department or regional Poison control Centre immediately, even if there are no symptoms.

Missed Dose:

If you have forgotten to take your dose during the day, carry on with the next one at the usual time. Do not double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Side effects may include:

- muscle cramps, spasms, and pain, weakness, restlessness
- dizziness, pins and needles in your fingers, headache, being in a daze, trouble sleeping, nervousness, sleepiness, fatigue, tiredness
- constipation, diarrhea, nausea, vomiting, decreased appetite, upset stomach, enlargement of the glands in your mouth, stomach pain, hiccups, thirst, gas, bad taste, dry mouth
- reduced libido
- bleeding under the skin, rash, red patches on the skin, itching, flushing
- stuffy nose

If any of these affects you severely, tell your doctor, nurse or pharmacist.

AA-AMILZIDE can cause abnormal blood test results. Your doctor will decide when to perform blood tests and will interpret the results.

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

| Symptom / effect | | Talk with your doctor, nurse, or pharmacist | | Stop taking drug and seek immediate medical help |
|------------------|---|---|--------------|--|
| | | Only if severe | In all cases | |
| Common | Low Blood Pressure: dizziness, fainting, lightheadedness. May occur when you go from lying or sitting to standing up. | √ | | |
| | Decreased levels of potassium in the blood: irregular heartbeats, muscle weakness and generally feeling unwell | | √ | |

| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | | | | |
|---|--|---|--------------|--|
| Symptom / effect | | Talk with your doctor, nurse, or pharmacist | | Stop taking drug and seek immediate medical help |
| | | Only if severe | In all cases | |
| | <p>Non-melanoma skin cancer: lump or discoloured patch on the skin that stays after a few weeks and slowly changes. Cancerous lumps are red/pink and firm and sometimes turn into ulcers. Cancerous patches are usually flat and scaly.</p> | | √ | |
| Uncommon | <p>Allergic Reaction: rash, hives, swelling of the face, lips, tongue or throat, difficulty swallowing or breathing</p> | | | √ |
| | <p>Kidney Disorder: change in frequency of urination, nausea, vomiting, swelling of extremities, fatigue</p> | | √ | |
| | <p>Liver Disorder: yellowing of the skin or eyes, dark urine, abdominal pain, nausea, vomiting, loss of appetite</p> | | √ | |
| | <p>Increased blood sugar: frequent urination, thirst, and hunger</p> | √ | | |

| SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM | | | | |
|---|--|---|--------------|--|
| Symptom / effect | | Talk with your doctor, nurse, or pharmacist | | Stop taking drug and seek immediate medical help |
| | | Only if severe | In all cases | |
| | <p>Electrolyte Imbalance: weakness, drowsiness, muscle pain or cramps, irregular heartbeat</p> | | √ | |
| | <p>Gastrointestinal bleeding: black stool or blood in stool</p> | | √ | |
| | <p>Depression: feeling sad, not interested in usual activities, weight change and sleep disruptions</p> | √ | | |
| | <p>Mental confusion: Inability to know the date, where and who you are</p> | √ | | |
| | <p>Angina: Chest pain</p> | | | √ |
| Rare | <p>Decreased Platelets: bruising, bleeding, fatigue and weakness</p> | | √ | |
| | <p>Decreased White Blood Cells: infections, fatigue, fever, aches, pains, and flu-like symptoms</p> | | √ | |
| Very rare | <p>Toxic Epidermal Necrolysis: severe skin peeling, especially in mouth and eyes</p> | | | √ |

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

| Symptom / effect | | Talk with your doctor, nurse, or pharmacist | | Stop taking drug and seek immediate medical help |
|------------------|--|---|--------------|--|
| | | Only if severe | In all cases | |
| Unknown | Eye Disorders: - Myopia: sudden near sightedness or blurred vision - Glaucoma: increased pressure in your eyes, eye pain | | | √ |
| | Anemia: fatigue, loss of energy, weakness, shortness of breath. | | √ | |
| | Inflammation of the Pancreas: abdominal pain that lasts and gets worse when you lie down, nausea, vomiting | | √ | |
| | Hepatic encephalopathy : forgetfulness, confusion, irritability, sleeping during the day and being awake at night | | | √ |
| | Necrotizing angitis: fever, stomach pain, numbness and tingling in the hands and feet, swelling in the hands, ankles or feet, changes in frequency of urination | | | √ |
| | Respiratory distress: trouble breathing, shortness of breath, skin turning blue around the mouth, lips and fingernails | | | √ |

while taking AA-AMILZIDE, contact your doctor, nurse, or pharmacist.

HOW TO STORE IT

Store at room temperature (15°C to 30°C).

Keep out of reach and sight of children.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

If you want more information about AA-AMILZIDE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this consumer information by visiting the Health Canada website (<https://health-products.canada.ca/dpd-bdpp/index-eng.jsp>); the manufacturer's website <https://www.aapharma.ca/en/>, or by calling 1-877-998-9097.

This leaflet was prepared by AA Pharma Inc.

Last revised: June 06, 2019

This is not a complete list of side effects. For any unexpected effects